Reimbursed Care Access in India

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Enforcement and case law have produced some narrow factual nuances (for example, a recent high‑court observation distinguishing fungal material from listed psychotropic mixtures in a bail order), but there is no established, reimbursed medical psilocybin program in India and possession/supply remains subject to NDPS enforcement. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is seized and prosecuted under NDPS provisions and is not reimbursed or legally available for routine medical practice in India. Recent enforcement actions and seizures are frequently reported. # #

Esketamine (Spravato) has regulatory approvals in some jurisdictions internationally, but it is not established as a widely available, reimbursed therapy in India and there is no public programme providing routine coverage similar to some western markets. Commercial commentary and specialist centres in India report that Spravato is not marketed/established in India and that ketamine‑based therapies in India are largely delivered as off‑label ketamine infusions rather than a licensed esketamine nasal product. Private out‑of‑pocket provision or referral abroad are the dominant practical pathways for access when sought. # #

Ketamine is a legally regulated medicinal anesthetic in India and is used in routine anesthetic practice; since 2010 regulators increased supply controls (prescription / Schedule X controls) due to diversion/misuse concerns. In psychiatry it is commonly used off‑label (intravenous, intramuscular or intranasal compounded preparations) in private clinics for treatment‑resistant depression, suicidality and other indications — these private off‑label treatments are typically paid out‑of‑pocket and are not covered under standard public reimbursement schemes. There is not a nationally standardised, publicly reimbursed ketamine‑for‑depression programme; protocols, supervision (psychiatrist vs anesthesiologist), and monitoring requirements vary by provider and state practice. Clinicians and commentators in India explicitly note absence of a legal requirement for anesthetist supervision for sub‑anesthetic psychiatric protocols, but emphasise need for informed consent and structured protocols. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no authorised, reimbursed medical DMT programme in India and possession, manufacture or supply is enforceable under the NDPS Act. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no established clinical or reimbursed pathway for 5‑MeO‑DMT in India, and activities involving the compound are subject to NDPS enforcement. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not part of any reimbursed addiction‑treatment programme in India and use or supply would be subject to prosecution under NDPS controls. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The DMT and MAO‑inhibitor components that give ayahuasca psychoactive effects are controlled substances in India; traditional sacramental or religious exemptions common in other countries do not create an established legal, reimbursed pathway in India. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and peyote preparations containing it) are not part of any authorised, reimbursed therapeutic programme in India and are subject to NDPS enforcement on possession and supply. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family (e.g., 2C‑B/2C‑E) is treated as prohibited psychotropic compounds for supply/possession and no reimbursed medical programmes exist in India. Law‑enforcement seizures and prosecutions are regularly reported. #